About Us
Sepal Pharma is a biopharmaceutical company that develops safe cancer therapies targeting the energy synthesis systems within tumor cells with a unique and specific mode of action. The company's portfolio of drug-candidates targets a wide range of cancer types while displaying none of the side effects that result from classical cytotoxic cancer drugs.Sepal Pharma is exploring a new therapeutic class for cancer treatment based on jasmonate derivatives, working in collaboration with the group of Professor Flescher in Tel Aviv University leader in the field of anticancer effect of Jasmonates, and Professor Varda Shoshan Barmatz, world expert in the field of mitochondrial hexokinases, The research relies on an earlier observation by Professor Flescher, which demonstrated that derivatives from the natural compound methyl-Jasmonate kill cancer cells by targeting the overactive energy synthesis metabolism characteristic of tumor cells, without affecting that of normal cells.
A broad patent portfolio protects the Company's technology, with several patents granted in EU and US.
Founded in 2003, Sepal Pharma has built a strong and experienced Management team, which focuses on the design, preclinical characterization and early clinical development of drug candidates. Together with its Board of Directors and Scientific Advisory Board the company regroups world-renowned experts in the field of bioenergetics research, drug discovery, clinical development in cancer, and corporate development.
The company operates by outsourcing its lab operations to specialized external organizations. Its mode of operation combined with its unique set of skills insures Sepal Pharma an optimized track to successful safe cancer therapies.
